Analysis of Human ALS Tissues and Registry of ALS Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorUniversity of Illinois at Chicago

About this trial

Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite years of intensive research, a fundamental understanding of this disease is still lacking. There is a need to identify both reliable markers of disease progression and effective treatments. The goal of this research is to bring a greater understanding of ALS patients closer to the research studies that can lead to new hypotheses and approaches.

Eligibility criteria

Qualifiers

Patients over the age of 18

Established diagnosis of ALS

Able and willing to give written informed consent and must authorize release and use of protected health information

Disqualifiers

Patients below the age of 18

No diagnosis of ALS

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

University of Illinois at Chicago

Lead sponsor

Tanabe Pharma America, Inc.

Collaborator